BDR News and Press, Blonder Tongue Laboratories Inc. From 02/07/19

Atossa Genetics (NASDAQ: ATOS ) +29%  on updating the status of the pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient who received preoperative oral Endoxifen therapy under an FDA-approved “expanded access” program. More news on: Atossa Genetics, ...